Ivermectin associated adverse events in the treatment and prevention of COVID-19 reported to the FACT pharmacovigilance project (2022)

Peer-Reviewed Study · Farah R, Kazzi Z, Brent J, Burkhart K, Wax P, Aldy K, et al. · August 2022

Farah R et al., 2022-08: Prospective case series of 40 ivermectin adverse events reported to the FDA/ACMT COVID-19 ToxIC registry from 15 academic centres, 25 of them severe and neurological toxicity the commonest finding. Self-medication with veterinary formulations accounted for 18 of the 40.

Neurological toxicity was the most frequent finding. Fifteen patients had minor symptoms while 25 developed severe toxicity.

Farah R et al., 2022-08: Prospective case series of 40 ivermectin adverse events reported to the FDA/ACMT COVID-19 ToxIC registry from 15 academic centres, 25 of them severe and neurological toxicity the commonest finding. Self-medication with veterinary formulations accounted for 18 of the 40. C4 toxico-surveillance. Study type: prospective case series (voluntary toxico-surveillance sub-registry); N=40 over 15 months (October 2020-December 2021); United States (15 academic medical centres, 12 states). Dose: recorded per case in the registry but not summarised in the abstract. 18/40 self-medicated with veterinary formulations; 33 presented to emergency departments; 19 admitted. Comparator: none. Funder: FDA ACMT COVID-19 ToxIC (FACT) project; individual author conflicts not recorded in the PubMed record. Study type: uncontrolled series.